CJC-1295 with DAC vs IGF-1 DES — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
CJC-1295 with DAC is a long-acting GHRH analog that uses a Drug Affinity Complex (DAC) technology - a reactive maleimidoproprionic acid linker that covalently bonds to plasma albumin after injection. This albumin binding dramatically extends its half-life to 6-8 days, allowing on...
Calculate CJC-1295 with DAC dose →IGF-1 DES (des(1-3)IGF-1) is a naturally occurring truncated form of IGF-1, produced endogenously in the brain and other tissues, that lacks the first three N-terminal amino acids (Gly-Pro-Glu) of full-length IGF-1. This truncation eliminates its binding to IGF-binding proteins (...
Calculate IGF-1 DES dose →| Parameter | CJC-1295 with DAC | IGF-1 DES |
|---|---|---|
| Category | Growth Hormone & IGF | Growth Hormone & IGF |
| Research | Research Use | Research Use |
| Half-Life | 6–8 days | 20–30 minutes (shorter than IGF-1 LR3) |
| Typical Dose | 1,000–2,000 µg | 50–100 µg |
| Frequency | Once or twice weekly | 1–2x daily (peri-workout) |
| Route | Subcutaneous | Subcutaneous / Intramuscular (local) |
| FDA Status | Not Approved | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.